| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Networking > Reviewing Your Networking Schedule |
|
Digg It - Reviewing Your Networking Schedule
I think most of us are pretty sold on the idea of extending our networks. Knowing more people gives you a greater o According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product pportunity to be of service. Like many other marketing activities, networking requires an investment – of your mone ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in , your time and your commitment. So before paying again for another year’s membership, take a moment to analyse whe lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ther this investment has given you the return you expected. Firstly, did you commit fully to the network over the here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ast year. Did you go to meetings regularly, make an effort to meet new people, and then keep in touch with them aft d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro erwards? Did you join a committee or become involved in the management of the group? If you haven’t made the grade ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc by participating fully in a network, then you shouldn’t expect a big return. Your decision on whether to stay with easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi this particular network should revolve around whether you plan to put in 100% effort for the next 12 months. Howev nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically r, if you can say - hand on heart - that you invested the right amount of time, then the question really does becom and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ e about what you got out of it. Here’s a list of things to consider: How many new contacts did you make ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi hat you would feel comfortable contacting? How much new business did you get as a result of being par ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a of the network? How valuable was the content of the events you attended? What did you learn that has dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod helped you or your business? How much did you enjoy mixing with the other members? How cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin much time did you invest with each network? What was the total cost of being with the network for the tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen last 12 months? How relevant was the network to the type of business you run? When you start to art t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel culate some of these things, it will quickly become clear whether you should stay or move on from each group. Netw ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust orking is one of my key marketing activities (along with writing…), so I make sure I review my success with various y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products networks on a regular basis. I have recently decided not to rejoin one of my networks, but to substitute it with i . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nvolvement in 2 industry bodies. And don’t be afraid to quit a network if it isn’t working for you (providing you’ elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip e put the effort in to making it work of course), or if your business changes and other things become more relevant tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Three Ways to Streamline Your Business Seven Steps You Need to Take Now to Compete in the Twenty-first Century Reality Branding - Are You Taking Advantage Of The 40 Year Social Pendulum?
|